Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy
Research · 01.01.2026 · 9
DOI: 10.34133/research.1210 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 14.04.2026. Verfasst von Huifang Shi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, The Rizhao People's Hospital Affiliated to Jining Medical University, Rizhao 276826, Shandong, China. Die Arbeit nennt 170 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Recently, immune checkpoint inhibitors (ICIs) have demonstrated substantial benefits and potential by enhancing antitumor immune responses via the normalization of host T cell activity. Nonetheless, a considerable proportion of patients were tolerant to ICI therapy, thereby restricting its broader application in cancer treatment. Identifying the key barriers responsible for resistance to ICI therapy has led to the development of combination therapies with ICIs as a promising approach to overcome these challenges, providing new directions for ICI-based cancer immunotherapy. Neutrophils within the tumor microenvironment are considered a critical factor contributing to poor responses to ICI treatment, and combining ICIs with neutrophil-targeted therapy has shown remarkable efficacy and promise. Consequently, this review discusses the diverse roles of neutrophils in cancer immunotherapy, outlines the synergistic mechanisms of targeting neutrophils in conjunction with ICIs, highlights relevant clinical trials of this combination strategy, and discusses current limitations and future directions. Overall, this review aims to provide new insights into effective strategies for ICI therapy.
Autor:innen und Institutionen
- Clinical Laboratory, The Rizhao People's Hospital Affiliated to Jining Medical University, Rizhao 276826, Shandong, China.
- Blood Transfusion Department, The Rizhao People's Hospital Affiliated to Jining Medical University, Rizhao 276826, Shandong, China.
- Department of Anesthesiology, The Rizhao People's Hospital Affiliated to Jining Medical University, Rizhao 276826, Shandong, China.
- Center for Vascular Biology and Translational Medicine, Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao 266021, China.
ORCID-Profile: Tao Yu
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Shi, H., Wang, J., Wang, Z., Li, Y., Yu, T., Qin, Y., & Lv, J. (2026). Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy. Research, 9. https://doi.org/10.34133/research.1210
Vancouver
Shi H, Wang J, Wang Z, Li Y, Yu T, Qin Y, et al. Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy. Research. 2026;9. doi:10.34133/research.1210
BibTeX
@article{Shi2026,
author = {Shi, Huifang and Wang, Jiaan and Wang, Ziyi and Li, Yuanyuan and Yu, Tao and Qin, Yan and Lv, Jie},
title = {Synergistic Potential of Immune Checkpoint Inhibitor Combined with Neutrophil-Targeted Therapy in Cancer Immunotherapy},
journal = {Research},
year = {2026},
volume = {9},
doi = {10.34133/research.1210}
}
EUVIMED